Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
Bradley Alexander McGregorWanling XieElio AdibWalter M StadlerYousef ZakhariaAijai AlvaM Dror MichaelsonShilpa GuptaElaine T LamSubrina FarahAmin H NassarXiao X WeiKerry L KilbridgeLauren C HarshmanSabina SignorettiLynette M ShollDavid J KwiatkowskiRana R McKayToni K ChoueiriPublished in: JCO precision oncology (2022)
Sapanisertib had minimal activity in treatment-refractory mRCC independent of mTOR pathway alterations. Additional therapeutic strategies are needed for patients with refractory mRCC.